zalcitabine has been researched along with HIV Coinfection in 378 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 307 (81.22) | 18.2507 |
| 2000's | 61 (16.14) | 29.6817 |
| 2010's | 10 (2.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Abad-Carrillo, MA; Álvarez-Ríos, AI; Bernal-Morell, E; Genebat, M; González-García, J; Herrero-Fernández, I; Leal, M; Montero, M; Pacheco, YM; Pulido, F; Rosado-Sánchez, I; Ruiz-Mateos, E; Vidal, F | 1 |
| Fang, Z; Gao, Y; Jia, T; Li, G; Liang, S; Liu, S; Ouyang, S; Wang, S; Wu, B; Xie, L; Xu, C; Xu, H; Xue, Y; Yi, Z; Yuan, H; Zhang, C; Zhao, S; Zhou, C; Zou, L | 1 |
| Candiotti, KA; Hao, S; Huang, W; Kanao, M; Kanda, H; Levitt, RC; Liu, S; Lubarsky, DA; Yi, H | 1 |
| Blackbeard, J; Dickenson, AH; Hasnie, FS; Hosseini, R; Jina, N; Maratou, K; McMahon, SB; Okuse, K; Orengo, C; Pheby, T; Rice, AS; Wallace, VC | 1 |
| Colucci, P; Ducharme, MP; Hoepelman, IM; Pottage, JC; Robison, H; Schürmann, D; Turgeon, J | 1 |
| López Bernaldo de Quirós, JC | 1 |
| Ghosh, D | 1 |
| Balcarek, K; Beauvoit, B; Bonnet, J; Deveaud, C; Kirschner, J; Lebrecht, D; Venhoff, AC; Venhoff, N; Walker, UA | 1 |
| Berrino, L; Scaglione, F | 1 |
| Blackbeard, J; Field, MJ; Hasnie, F; O'Dea, KP; Pheby, T; Rice, AS; Segerdahl, A; Takata, M; Wallace, VC | 1 |
| Domínguez Castellanos, A; Justo Alpañés, E; Orbea Ríos, L | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Mitra, AK; Patel, J | 1 |
| Aboulker, JP; Brun-Vézinet, F; Descamps, D; Flandre, P; Izopet, J; Joly, V; Meiffrédy, V; Tamalet, C | 1 |
| Macher, A; Paul, SM; Thomas, D | 1 |
| Casula, M; de Ronde, A; Goudsmit, J; Lange, JM; Reiss, P; Weverling, GJ | 1 |
| Bäuerle, J; Gatell, JM; Laguno, M; Mallolas, J; Mauss, S; Miquel, R; Murillas, J; Schmutz, G; Setzer, B; Walker, UA | 1 |
| Almond, MR; Liotta, DC; Mao, S; Painter, GR | 1 |
| Mukai, E | 1 |
| Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
| Otto, MJ | 1 |
| Beard, A; Cartee, L; De La Rosa, A; Kravec, I; McBrayer, TR; Murphy, RL; Otto, MJ; Schinazi, RF; Schürmann, D; Stuyver, LJ | 1 |
| Sax, PE | 1 |
| Back, N; Bakker, M; Berkhout, B; de Ronde, A; Jebbink, MF; Jurriaans, S; Parkin, N; Reiss, P; van der Hoek, L | 1 |
| Hurwitz, SJ; Otto, MJ; Schinazi, RF | 1 |
| Arastèh, K; Beard, A; Cartee, L; Drauz, D; Herzmann, C; Kreckel, P; Murphy, RL; Otto, MJ; Schinazi, RF; Schulbin, H | 1 |
| Dettrairat, S; Klinbuayaem, V; Kunachiwa, W; Leechanachai, P; Leenasirimakul, P; Sangkitporn, S; Shide, L; Thamlikitkul, V; Wirayutwatthana, NA | 1 |
| Susman, E | 1 |
| Feinberg, J | 1 |
| de Baar, MP; de Ronde, A; Ruiter, JP; Tebas, P; Timmermans, EC; Wanders, RJ | 1 |
| Karandreas, N; Kokotis, PI; Konstantinou, K; Kontos, AN; Kordossis, T; Panayiotakopoulos, GD; Skopelitis, EE | 1 |
| Chiche, L; Cretel, E; Durand, JM; Figuarella-Branger, D; Jean, R | 1 |
| Grier, JP; Hernandez-Santiago, BI; Mathew, JS; Rapp, KL; Schinazi, RF | 1 |
| Borjabad, A; Chao, W; Hadas, E; Ichiyama, K; Potash, MJ; Saini, M; Volsky, DJ | 1 |
| Johnston, E; Kassaye, SG; Katzenstein, DA; Shulman, NS; Winters, MA | 1 |
| Faetkenheuer, G; Hartmann, P; Jung, N; Knispel, M; Lehmann, C; Rubbert, A; Stellbrink, HJ; Taubert, D; van Lunzen, J | 1 |
| Arenas-Pinto, A; Bhaskaran, K; Dunn, D; Weller, IV | 1 |
| González-Lahoz, J; Soriano, V | 1 |
| Nelson, H | 1 |
| Benoit, SL; Eron, JJ; Fallon, MA; Jemsek, J; Kuritzkes, DR; MacArthur, RD; Quinn, JB; Rubin, M; Santana, J | 1 |
| Merigan, TC | 1 |
| Balfour, HH; Erice, A | 1 |
| Caliendo, AM; Hirsch, MS | 1 |
| Britton, S; Julander, I | 1 |
| Christopherson, C; Collis, P; Danner, SA; de Jong, D; Loveday, C; Mulder, J; Nijhuis, M; Schipper, P; Schuurman, R; van Leeuwen, R | 1 |
| Harrigan, PR; Kemp, SD; Larder, BA | 1 |
| Clifford, DB; Fichtenbaum, CJ; Powderly, WG | 1 |
| Abrams, D; DeMets, DL; Fleming, TR; Goldman, A; Korvick, J; Launer, C; Neaton, JD | 1 |
| Farr, SS; Kammerman, LA; Kazempour, K | 1 |
| Choo, V | 1 |
| Dillner, L | 1 |
| Stretcher, BN | 1 |
| Chadwick, EG; de Dennis, SR; Massarella, JW; Nazareno, LA; Nieuwenhuis, TJ; Williams, K; Yogev, R | 1 |
| Devineni, D; Gallo, JM | 1 |
| Gunnarsson, G; Hammer, SM | 1 |
| Hoernle, EH; Reid, TE | 1 |
| Kamali, F | 1 |
| Anderson, BD; Kojima, E; Mitsuya, H; Shirasaka, T; Yarchoan, R | 1 |
| Lissen, E | 1 |
| Simpson, DM; Tagliati, M | 1 |
| Boucher, CA; Hill, A; Ingrand, D; Katlama, C; Kitchen, V; McBride, M; McDade, H; Tubiana, R; van Leeuwen, R; Weber, J | 1 |
| Khoo, SH; Wilkins, EG | 1 |
| Cooley, TP; Hirst, HM; Montaner, JS; Pluda, JM; Quinn, JB; Reinhalter, NE; Ruedy, J; Shay, LE; Vicary, CA; Warthan, SN | 1 |
| Brivet, FG; Dormont, J; Lemaigre, GF; Naveau, SH | 1 |
| Richman, DD | 1 |
| Johnson, VA | 2 |
| Spector, SA | 1 |
| Dormont, J | 1 |
| Benhamou, Y; Dohin, E; Gentilini, M; Huraux, JM; Katlama, C; Lunel-Fabiani, F; Opolon, P; Poynard, T | 1 |
| Dudley, MN | 1 |
| Carpenter, CC; Cobbs, CG; Holmes, KK; Sande, MA; Sanford, JP | 1 |
| Lancaster, DJ; Lancaster, LL | 1 |
| Fischl, MA; Lai, S; Meng, TC; Resnick, L; Richman, DD; Spector, SA | 1 |
| Abrams, DI; Crane, LR; Goldman, AI; Grodesky, M; Kornegay, S; Korvick, JA; Launer, C; Muth, K; Neaton, JD; Wakefield, S | 1 |
| Craib, KJ; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Schechter, MT; Strathdee, SA | 1 |
| Hirschel, B | 1 |
| Grange, JM; Hamedi-Sangsari, F; Malley, SD; Vila, JR | 1 |
| Lüthy, R | 1 |
| Morris, DM; Selinger, K | 1 |
| Volberding, PD | 1 |
| Lipsky, JJ | 1 |
| Fischl, MA; Follansbee, SE; Frame, PT; Henry, DH; Lalezari, JP; Lieberman, J; Lin, AH; Nauss-Karol, C; Olson, RM; Remick, SC; Salgo, MP; Soo, W | 1 |
| Morse, GD; O'Donnell, AM; Shelton, MJ | 1 |
| Saag, MS | 2 |
| Bergé, P; Mildvan, D; Salgo, M; St Clair, M; Starrett, S | 1 |
| Volberding, PA | 1 |
| Cinatl, J; Doerr, HW; Kornhuber, B; Mainke, M; Rabenau, H; Weber, B; Weissflog, A | 1 |
| Armbrecht, C; Hengels, KJ; Jablonowski, H; Manegold, C; Mauss, S; Szelenyi, H | 1 |
| Mayaud, C | 1 |
| Baranowski, E; Kaulen, P; Pham, DT; Wollensak, J | 1 |
| Dionne, G; Gao, Q; Gu, Z; Hiscott, J; Wainberg, MA | 1 |
| Lang, W; Moss, A; Osmond, D; Page-Bodkin, K; Winkelstein, W | 1 |
| Arezzo, JC; Berger, AR; Bozzette, S; Merigan, T; Richman, D; Schaumburg, HH; Skowron, G; Soo, W | 1 |
| Bucher, GG | 1 |
| Edelman, K; Hooker, M; Muirhead, GJ; Rousseau, FS; Sereni, D; Williams, PE | 1 |
| D'Aquila, RT; Hirsch, MS | 1 |
| Meyer, C | 1 |
| Costigliola, P; Degrassi, A; Facchini, A; Lisignoli, G; Monaco, MC; Ricchi, E; Toneguzzi, S | 1 |
| Cooper, DA; Emery, S | 1 |
| Gerstoft, J; Pedersen, BK | 1 |
| Abrams, DI; Carlin, BP; Crane, LR; Deyton, L; Goldman, AI; Korvick, JA; Launer, C | 1 |
| Barbosa, P; Buchbinder, S; Feinberg, M; Harrer, E; Harrer, T; Johnson, RP; Walker, BD | 1 |
| Holazo, AA; Limjuco, R; Massarella, JW; Min, B; Nazareno, LA; Passe, S; Twardy, SK | 1 |
| Hui, F; Kavlick, MF; Kojima, E; Mitsuya, H; Pluda, JM; Shirasaka, T; Yarchoan, R | 1 |
| Pinching, AJ | 1 |
| Jablonowski, H | 1 |
| Staszewski, S | 1 |
| Baruch, A; Bassett, RL; Collier, AC; Coombs, RW; Corey, L; Facey, K; Friedman, HM; Hooper, C; Jones, M; McAuliffe, VJ; Merigan, TC; Reichman, RC; Schoenfeld, DA; Timpone, J; Whitacre, C | 1 |
| Boucher, CA; Cammack, N; Hill, A; Ingrand, D; Loveday, C; Robert, C; Weber, J | 1 |
| Adams, O; Jablonowski, H; Mauss, S; Willers, R | 1 |
| Acosta, EP; Henry, K; Jochimsen, E | 1 |
| Chambers, DE; Cooper, DA; Crowe, S | 1 |
| Boehme, R; Bonhoeffer, S; Hill, AM; McDade, H; Nowak, MA; Thomas, HC | 1 |
| Borkow, G; Castriota, G; Drosopoulos, WC; Gu, Z; Hsu, M; Islam, S; Manne, J; Parniak, M; Prasad, VR; Salomon, H; Song, Q; Wainberg, MA | 1 |
| Brunet, C; Conciatori, M; Courcoul, M; Dhiver, C; George, F; Guillemain, C; Horschowski, N; Sampol, J; Spire, B | 1 |
| Nathan, R | 1 |
| Besley, D; Graham, NM; Jacobson, LP; Muñoz, A; Murphy, R; Park, LP; Zucconi, S | 1 |
| Cooper, DA; Harrigan, PR; Kinghorn, I; Lange, JM; Larder, BA; Lavelle, J; Lefkowitz, L; McKinnis, R; Moore, M; Mulder, JW; Pennington, KN; Ramirez-Ronda, C; Rooney, JF; Schooley, RT; St Clair, M; Steel, H | 1 |
| Balis, F; Brouwers, P; Church, J; Farley, M; Goldsmith, J; Keller, A; Lewis, LL; Mueller, B; Pizzo, PA; Rubin, M; Shearer, GM; Sloas, M; Venzon, D; Wheeler, S; Wood, L; Yuen, G | 1 |
| Danner, SA; Dellarnonica, P; Harrigan, PR; Hill, AM; Johnson, MA; Loveday, C; McDade, H; Picazo, JJ; Skinhøj, P; Staszewski, S; Verity, L | 1 |
| Clumeck, N; Hill, AM; Ingrand, D; Johnson, M; Katlama, C; Loveday, C; Mallolas, J; McDade, H; Pearce, G; Staszewski, S | 1 |
| Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD | 1 |
| Bartlett, JA; Benoit, SL; Ehmann, WC; Fallon, MA; Johnson, VA; Quinn, JB; Rubin, M; Self, PL; Sepulveda, GE; Tsoukas, C | 1 |
| Rowe, PM | 1 |
| de Mendonça, JS | 1 |
| Rosenthal, C | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Childress, JF; DeMets, DL; Ellenberg, SS; Fleming, TR; Foulkes, M; Mayer, KH; O'Fallon, J; Pollard, RB; Rahal, JJ; Whitley, RJ | 1 |
| Andries, K; De Brabander, M; De Crée, J; De Raeymaeker, M; Miller, V; Moeremans, M; Pearce, G; Peeters, M; Rehmet, S; Stark, T; Staszewski, S; Stoffels, P; Van den Broeck, R; Verbiest, W | 1 |
| Abraham, T; Nusbaum, NJ | 1 |
| Boulton, A | 1 |
| Gerberding, JL | 1 |
| André, E; Bez, G; Bourdillon, F; Delfraissy, JF; Nadal, JM | 1 |
| Ho, DD | 1 |
| Corey, L; Holmes, KK | 1 |
| Skowron, G | 2 |
| Lane, HC; Masur, H; Spooner, KM | 1 |
| Marcus, U | 1 |
| Faulds, D; Lea, AP | 1 |
| Cohen, LG; Noormohamed, SE | 1 |
| Hoof, T | 1 |
| Carr, A; Cooper, DA; Emery, S; Kelleher, A; Law, M | 1 |
| Barber, CG; Hogg, R; Montaner, JS; Murphy, C; O'Shaughnessy, M; Phillips, P; Schechter, MT; Srour, LF | 1 |
| Moyle, GJ | 1 |
| Balagué, M; Cabrera, C; Clotet, B; De Clercq, E; Martínez-Picado, J; Puig, T; Romeu, J; Ruiz, L; Schmit, JC; Segura, A; Sirera, G; Tural, C; Vandamme, AM | 1 |
| Zaretsky, MD | 1 |
| Fornairon, S; Idatte, JM; Lesprit, P; Michaut, P; Modaï, J; Nochy, D | 1 |
| Millard, PS | 1 |
| Antela, A; Parras, F; Podzamczer, D; Ruiz, I | 1 |
| Gatell, JM; Guerra, L; Pérez-Elías, MJ; Santamaría, JM | 1 |
| Aguirrebengoa, K; Mallolas, J; Torres Tortosa, M; Uriz, J | 1 |
| Bascuñana, A; Laguna, F; Ocaña, I; Pulido, F | 1 |
| Augenbraun, M; Minkoff, H | 1 |
| Fenwick, JD; Monte, S; Monteiro, EF | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Heins, JR | 1 |
| Bakshi, SS; Boone, G; Britto, P; Capparelli, E; Fowler, MG; Frank, Y; Jimenez, E; Mofenson, L; Pahwa, SG; Rasheed, S; Salgo, M; Schoenfeld, D; Yogev, R; Zimmer, B | 1 |
| Craig, C; Moyle, G | 1 |
| Costello, CE; Nelson, MR; Walsh, JC | 1 |
| Brizzi, M; Ceccherini-Nelli, L; Forastieri, G; Iuliano, R; Mazzotta, F; Mecocci, L | 1 |
| Adkins, JC; Faulds, D; Peters, DH | 1 |
| Bonsel, GJ; Danner, SA; Lange, JM; Reiss, P; van Leeuwen, R | 1 |
| Blanchard, S; Dankner, WM; Hodes, D; McIntosh, K; McNamara, J; Oleske, JM; Salgo, M; Spector, SA; Wara, DW | 1 |
| Autran, B; Blanc, C; Carcelain, G; Debré, P; Katlama, C; Leibowitch, J; Li, TS; Mathez, D; Tubiana, R | 1 |
| Böhler, T; Debatin, KM; Geiss, M; Haas, J; Herr, I | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Boucher, C; Brun-Vézinet, F; Descamps, D; Fauveau, V; Izopet, J; Jeffries, D; Kaye, S; Krzyanowski, C; Loveday, C; Nunn, A; Schuurman, R; Seigneurin, JM; Tamalet, C; Tedder, R; Weber, J; Weverling, GJ | 1 |
| Blaschke, TF; Collier, AC; Gries, JM; Kastrissios, H; Park, K; Sheiner, LB; Squires, K; Vanhove, GF; Verotta, D | 1 |
| Blaschke, TF; Collier, AC; Coombs, R; Gries, JM; Sheiner, LB; Vanhove, GF; Verotta, D | 1 |
| Fischl, MA; Holden-Wiltse, J; Meehan, PM; Meng, TC; Richman, DD; Saag, M; Squires, KE | 1 |
| Becagli, P; Berto, V; Font, M; Martini, N; Messori, A; Tosolini, F; Trippoli, S; Venturini, F | 1 |
| Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S | 1 |
| Smith, IL; Spector, SA; Viani, RM | 1 |
| Byington, R; Elbeik, T; Fiscus, SA; Griffith, BP; Hammer, SM; Hughes, MD; Jackson, B; Japour, A; Katzenstein, DA; Lathey, JL; Pi, T; Rasheed, S; Reichman, R; Scott, W | 1 |
| Brettle, RP; Gore, S; Hutchinson, S; Leen, CL; Lewis, S; Morgan, R; Morris, S; Povey, S; Wilson, A | 1 |
| Conway, B; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Rhone, SA; Schechter, MT; Sherlock, C; Yip, B | 1 |
| DeMasi, R; Hill, AM; Montaner, JS | 1 |
| Burt, MS; Mills, RJ; Scott-Lennox, JA | 1 |
| Kavlick, MF; Mitsuya, H; Wyvill, K; Yarchoan, R | 1 |
| Stevens, TP; Watson, WJ; Weinberg, GA | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Bloch, J; Chavance, M | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Pineda, JA; Puig, T; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Puig, T; Rossau, R; Ruiz, L; Schmit, JC; Stuyver, L; Van Laethem, K; Vandamme, AM; Vanderlinden, I | 1 |
| Boucher, CA; Bruisten, SM; Huisman, JG; Loeliger, AE; Reiss, P; Schuurman, R; van Swieten, P; Weverling, GJ | 1 |
| Cammack, N; Dissanayeke, SR; Duncan, IB; Gilbert, SM; Moffatt, AR; Race, E; Rose, JS; Sheldon, JG; Sitbon, G | 1 |
| Clotet, B; Cruceta, A; García, F; Gatell, JM; Leal, M; Mallolas, J; Miró, JM; Pumarola, T; Ruiz, L; Tortajada, C; Vidal, C | 1 |
| Bachmeyer, C; Blum, L | 1 |
| Belec, L; Cotigny, S; Gilquin, J; Gutmann, L; Kazatchkine, M; Matta, M; Piketty, C; Si Mohamed, A; Weiss, L | 1 |
| Saag, MS; Schooley, RT | 1 |
| González-Lahoz, J; Jiménez-Nacher, I; Moreno Celda, V; Rodríguez-Rosado Martínez-Echevarría, R; Soriano Vázquez, V; Valencia Ortega, E | 1 |
| Arnedo, A; Mínguez, C; Olmos, P; Roca, B; Sáez-Royuela, A; Segarra, M; Simón, E; Teruel, C; Usó, J | 1 |
| Coolley, KL; Girard, YA; Hamdan, H; Katzenstein, DA; Levee, DJ; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Cassuto, JP | 1 |
| Ippolito, G; Puro, V | 1 |
| Gitterman, SR; Pratt, RD; Struble, KA | 1 |
| Fischer, T; Ramadori, G; Schwörer, H | 1 |
| Moyle, GJ; Sadler, M | 1 |
| Aquilina, C; Bonnet, E; Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sailler, L; Sandres, K | 1 |
| Fleury, S; Miedema, F; Otto, SA; Reiss, P; ten Kate, RW; van der Zee, AG; Wisman, GB; Wolthers, KC | 1 |
| Phillips, L | 1 |
| Flandre, P | 1 |
| Fischer, T; Ramadori, G; Reich, K; Schwörer, H; Vente, C | 1 |
| Barker, C; Moyle, G; Revicki, DA; Stellbrink, HJ | 1 |
| Martin, EM; Mullane, KM; Novak, RM; Pitrak, DL; Pursell, KJ | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arlotto, C; Bernard, A; Bernard-Pomier, G; Breittmayer, JP; Dellamonica, P; Pradier, C; Pugliese, P; Roger, PM | 1 |
| Arrizabalaga, J; Clotet, BG; Cruceta, A; Dalmau, D; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Grau, I; Knobel, H; Miró, JM; O'Brien, WA; Podzamczer, D; Pumarola, T; Romeu, J; Sambeat, MA | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| Avrămescu, C; Balasoiu, M; Radu, E; Turculeanu, A; Voiculescu, C | 1 |
| Collier, AC; Haubrich, R; Revicki, DA; Swartz, C; Wu, AW | 1 |
| Gazzard, BG; Moyle, GJ | 1 |
| Albrecht, H; Hufert, FT; Lauer, J; Racz, P; Schneider, C; Stellbrink, HJ; Tenner-Racz, K; van Lunzen, J | 1 |
| Aoki, M; Genka, I; Kikuchi, Y; Oka, S; Tachikawa, N; Teruya, K; Yamaguchi, M; Yamamoto, Y; Yasuoka, A; Yasuoka, C | 1 |
| Degenhardt, E; Glück, T; Grossmann, J; Lang, B; Schölmerich, J; Straub, RH | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Evans, C; Hermans, P; Muyldermans, G; Ruiz, L; Schmit, JC; Schneider, F; Simons, P; Stuyver, L; Van Laethem, K; Van Vaerenbergh, K; Van Wanzeele, F; Van Wijngaerden, E; Vandamme, AM; Verhofstede, C | 1 |
| Babiker, A; Collins, R; Darbyshire, J; Duncan, W; Foulkes, M; Hughes, M; Peto, R; Peto, T; Walker, A | 2 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Beylot, J; Dabis, F; Dequae-Merchadou, L; Marimoutou, C; Mercié, P; Morlat, P; Neau, D; Pellegrin, I | 1 |
| Ait-Khaled, M; Griffin, P; Kleim, JP; Rakik, A; Thomas, TA; Tisdale, M | 1 |
| Boschini, A; Calista, D | 1 |
| Bossi, P; Calvez, V; Delaugerre, C; Delfraissy, JF; Diquet, B; Do, B; Dohin, E; Katlama, C; Legrand, M; Mouroux, M; Peytavin, G; Trylesinski, A; Yvon-Groussin, A | 1 |
| Carey, P | 1 |
| Buranapraditkul, S; Chuenyam, M; Cooper, DA; Kroon, ED; Kunanusont, C; Lange, JM; Newell, ME; Phanuphak, P; Ruxrungtham, K; Sirivichayakul, S; Ubolyam, S; Ungsedhapand, C; van Leeuwen, R | 1 |
| Babiker, AG; Clarke, JR; Hooker, MH; Kaye, S; Tedder, R; Weber, JN | 1 |
| Cotton, DJ; Currier, JS; Grimes, J; Hammer, SM; Hughes, MD; Katzenstein, DA; Spino, C; Wofsy, CB | 1 |
| Albrecht, MA; Balfour, HH; Hammer, SM; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, MF; Valdez, H | 1 |
| La Seta Catamancio, S; Parker, D; Rusconi, S; Sheridan, F | 1 |
| Back, DJ; Hart, CA; Hoggard, PG; Kewn, S; Khoo, SH; Sales, SD; Sunderland, D | 1 |
| Arendt, G; Hefter, H; Theisen, A; von Giesen, HJ | 1 |
| Hirsch, MS; Yeni, P | 1 |
| Mascolini, M | 4 |
| Gilden, D | 3 |
| Cheng, B | 3 |
| Prescott, LM | 1 |
| James, JS | 6 |
| Poscher, M | 1 |
| Conant, M | 1 |
| Rubin, M | 1 |
| Japour, AJ | 1 |
| Vella, S | 1 |
| Levin, J | 1 |
| Baker, R | 2 |
| Chang, HE | 1 |
| Boucher, CA | 1 |
| Smart, T | 2 |
| Torres, G | 3 |
| MacDougall, DS | 2 |
| Cooper, EC | 1 |
| Randall, P | 1 |
| Doepel, L; Folkers, G | 1 |
| García-Díez, A; Jones-Caballero, M; Peñas, PF | 1 |
| Akintonwa, DA | 1 |
| Arduino, JM; Collier, AC; Fischl, MA; Spiegelman, D; Stanley, K | 1 |
| Blumoff, K; Garcia-Lerma, JG; Heneine, W; Nidtha, S; Weinstock, H | 1 |
| Aquilina, C; Calvez, V; Delfraissy, JF; Dohin, E; Goehrs, JM; Katlama, C; Lacoste, D; Lantz, O; Montestruc, F; Mouroux, M; Pellegrin, JL; Pialoux, G; Raffi, F; Raguin, G; Trylesinski, A; Vittecoq, D | 1 |
| Babiker, A; Darbyshire, J; Dunn, D; Hooker, M | 1 |
| Bacheler, L; Bazmi, H; Diamond, S; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Hammond, J; Klabe, R; Liotta, DC; Manion, DJ; Mellors, J; Otto, MJ; Pierce, M; Rayner, M; Schinazi, RF; Stuyver, L; Trainor, G; Wu, JT; Zhang, H | 1 |
| Brůcková, M; Linka, M; Reinis, M; Stanková, M; Vandasová, J | 1 |
| Danner, SA; Donn, KH; Hall, ST; Harker, AJ; Hussey, EK; Jonker, P; Lange, JM; van Leeuwen, R | 1 |
| Fauci, AS | 1 |
| Reddy, MM; Sakai, K; Volsky, B; Volsky, DJ | 1 |
| Indorf, AS; Pegram, PS | 1 |
| Nightingale, SL | 1 |
| Balzarini, J; Bergamini, A; Calio, R; De Clercq, E; Milanese, G; Pauwels, R; Perno, CF; Rocchi, G; Yarchoan, R | 1 |
| Husson, RN; Pizzo, PA | 1 |
| Hammer, SM; McLeod, GX | 2 |
| Garfunkel, AA; Glick, M | 1 |
| Bawdon, RE; Dax, J; Sobhi, S | 1 |
| Beretta, E; Bischi, GI; Solimano, F | 1 |
| Bassiakos, Y; Bennett, D; Boota, AM; Fischl, MA; Lai, SH; Meng, TC; Richman, DD; Spector, SA; Wright, B | 1 |
| Lane, HC | 1 |
| Cooper, DA; Danner, SA; Lange, JM | 1 |
| Albano, A; Brandi, G; Magnani, M; Rossi, L; Salvaggio, L; Schiavano, GF | 1 |
| Rousseau, F; Sereni, D | 1 |
| Fischl, MA | 1 |
| Butler, K; Husson, R; Marshall, D; Pizzo, PA; Roilides, E; Venzon, D | 1 |
| Cao, W; Fuchs, BA; Germolec, DR; Luster, MI; Munson, AE; Prejean, JD; Rosenthal, GJ; Shopp, G; Thompson, MB; Tomaszewski, JE | 1 |
| Hirsch, MS | 1 |
| Broder, S; Mitsuya, H; Perno, CF; Pluda, JM; Yarchoan, R | 1 |
| Fernández-Cruz, E | 1 |
| Cersosimo, RJ; Matthews, SJ; Spivack, ML | 1 |
| Basham, T; Holdener, T; Merigan, T | 1 |
| LeLacheur, SF; Simon, GL | 1 |
| Broder, S | 1 |
| Pizzo, PA | 1 |
| Bozzette, SA; Richman, DD | 1 |
| Broder, S; Yarchoan, R | 1 |
| Cotton, P | 1 |
| McGowan, J; Merigan, T; Sherwin, S | 1 |
| Broder, S; Mitsuya, H; Yarchoan, R | 1 |
| Bianchi, M; Bischi, GI; Magnani, M; Rossi, L; Solimano, F | 1 |
| Pizzo, PA; Roilides, E; Rubin, M; Venzon, D | 1 |
72 review(s) available for zalcitabine and HIV Coinfection
| Article | Year |
|---|---|
[Tenofovir DF in rescue regimens].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Clinical Trials, Phase III as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Multicenter Studies as Topic; Mutation; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Selection, Genetic; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zalcitabine | 2008 |
ACH-126443 Achillion/Yale University.
Topics: Animals; Clinical Trials as Topic; Hepatitis B; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Technology, Pharmaceutical; Zalcitabine | 2002 |
Contraindicated antiretroviral drug combinations.
Topics: Anti-Retroviral Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zalcitabine | 2003 |
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
Topics: Adenine; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Monophosphate; Deoxyribonucleotides; Dioxolanes; DNA, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; Humans; Kinetics; Molecular Structure; Nucleosides; Organophosphonates; Organophosphorus Compounds; Phosphorylation; Protein Binding; Protein Conformation; Purine Nucleosides; Reverse Transcriptase Inhibitors; Substrate Specificity; Tenofovir; Zalcitabine | 2004 |
[Neuromuscular diseases associated with HIV-1 infection].
Topics: Anti-HIV Agents; Cytomegalovirus Infections; HIV Infections; Humans; Neuritis; Neuromuscular Diseases; Peripheral Nervous System Diseases; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Zalcitabine; Zidovudine | 2004 |
New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Cytidine Triphosphate; Deoxycytidine; Dideoxynucleosides; Dioxolanes; Emtricitabine; HIV Infections; Humans; Purine Nucleosides; Reverse Transcriptase Inhibitors; Thionucleosides; Zalcitabine | 2004 |
Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
Topics: Antiviral Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Combination therapy for infection due to human immunodeficiency virus type 1.
Topics: Acyclovir; Antiviral Agents; CD4 Antigens; Clinical Trials as Topic; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Didanosine; Double-Blind Method; HIV Infections; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Zalcitabine; Zidovudine | 1995 |
Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Topics: Aging; Antineoplastic Agents; Antiviral Agents; Didanosine; Drug Interactions; Guidelines as Topic; HIV Infections; Humans; Phosphorylation; Racial Groups; Sex Characteristics; Stavudine; Zalcitabine; Zidovudine | 1995 |
Zalcitabine. Clinical pharmacokinetics and efficacy.
Topics: Animals; HIV Infections; Humans; Zalcitabine | 1995 |
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Topics: Antiviral Agents; Didanosine; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1995 |
Human immunodeficiency virus infection in children.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Dapsone; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pentamidine; Pneumonia, Pneumocystis; Pregnancy; Pregnancy Complications, Infectious; Recurrence; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1995 |
Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child; Didanosine; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Interferons; Needlestick Injuries; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1993 |
[Anti-HIV therapy (1987-1994): from nothing to confusion].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Time Factors; Zalcitabine; Zidovudine | 1995 |
Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.
Topics: Animals; Didanosine; Dideoxynucleosides; Disease Models, Animal; HIV Infections; Humans; Peripheral Nervous System Diseases; Stavudine; Zalcitabine | 1995 |
Controversies in anti-retroviral therapy of adults.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Complex; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1995 |
Pancreatic lesions in HIV-infected patients.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Didanosine; HIV Infections; Humans; Pancreas; Pancreatic Diseases; Pancreatitis; Pentamidine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine | 1994 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1994 |
Combination therapy: more effective control of HIV type 1?
Topics: Antiviral Agents; Controlled Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Virus Replication; Zalcitabine; Zidovudine | 1994 |
HIV therapy advances. Pediatric antiretroviral choices.
Topics: Body Weight; Clinical Trials as Topic; Didanosine; Female; Growth; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Treatment Failure; Zalcitabine; Zidovudine | 1994 |
Future treatment strategies in HIV infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Forecasting; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Clinical pharmacokinetics of nucleoside antiretroviral agents.
Topics: Animals; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients.
Topics: Adult; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance; Guidelines as Topic; HIV Infections; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1993 |
[Antiretroviral therapy. Current status and perspectives].
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Stavudine; Zalcitabine; Zidovudine | 1994 |
Perspectives on the use of antiretroviral drugs in the treatment of HIV infection.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Stavudine; Zalcitabine; Zidovudine | 1994 |
Zalcitabine and didanosine.
Topics: Adult; Antiviral Agents; Child; Didanosine; DNA Replication; DNA, Viral; Drug Interactions; HIV; HIV Infections; Humans; Virus Replication; Zalcitabine | 1993 |
Zalcitabine.
Topics: Adolescent; Adult; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; HIV Infections; Humans; Infant; Zalcitabine; Zidovudine | 1993 |
[Therapy of HIV infection with nucleoside analogs].
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nucleosides; Zalcitabine; Zidovudine | 1993 |
Therapy for human immunodeficiency virus infection.
Topics: Didanosine; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Protease Inhibitors; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1995 |
Studies of zidovudine in combination with didanosine and zalcitabine.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Safety; Zalcitabine; Zidovudine | 1995 |
Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Multicenter Studies as Topic; Zalcitabine; Zidovudine | 1996 |
Prophylaxis for occupational exposure to HIV.
Topics: Antiviral Agents; Health Personnel; HIV Infections; Humans; Lamivudine; Occupational Exposure; Protease Inhibitors; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
ddC (zalcitabine).
Topics: Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Meta-Analysis as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Ritonavir.
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; CD4-Positive T-Lymphocytes; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocyte Count; Randomized Controlled Trials as Topic; Ritonavir; RNA, Messenger; Zalcitabine; Zidovudine | 1996 |
Pediatric HIV infection: a primer for pharmacists.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pharmacists; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral treatment. Approach to previously treated patients].
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Initial anti-retroviral treatment (therapeutic approach to patients without previous treatment)].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral treatment. Treatment modification: toxicity management].
Topics: Anti-HIV Agents; Didanosine; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hematologic Diseases; HIV Infections; Humans; Muscular Diseases; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Antiretroviral therapy for pregnant women.
Topics: Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Zalcitabine; Zidovudine | 1997 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
The development of resistance of HIV-1 to zalcitabine.
Topics: Amino Acids; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Zalcitabine | 1997 |
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV-1; Humans; Zalcitabine | 1997 |
[Antiretroviral treatment in human immunodeficiency virus infection].
Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Toxicity of antiretroviral agents.
Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1998 |
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Finding a role for zalcitabine in the HAART era.
Topics: Anti-HIV Agents; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Saquinavir; Zalcitabine; Zidovudine | 1998 |
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 2000 |
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 2000 |
Peripheral neuropathy: zalcitabine reassessed.
Topics: Anti-HIV Agents; HIV Infections; Humans; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Risk Factors; Zalcitabine | 2000 |
New developments in antiretroviral drug therapy for HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Combinations; Drug Therapy, Combination; Gene Products, tat; HIV Infections; HIV-1; Humans; Protease Inhibitors; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine | 1992 |
The use of nucleoside analogues in the treatment of HIV-infected children.
Topics: Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Infant, Newborn; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Time Factors; Zalcitabine; Zidovudine | 1992 |
HIV disease: therapy, related systemic and oral conditions--an update.
Topics: Acquired Immunodeficiency Syndrome; Bacterial Infections; Didanosine; HIV Infections; Humans; Mouth Diseases; Mycoses; Sarcoma, Kaposi; Virus Diseases; Zalcitabine; Zidovudine | 1992 |
Current status of therapy for human immunodeficiency virus type 1.
Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Didanosine; Drug Resistance; HIV Infections; HIV Seropositivity; HIV-1; Humans; T-Lymphocytes, Helper-Inducer; Zalcitabine; Zidovudine | 1992 |
[Anti-HIV treatment, today and in the near future].
Topics: Antiviral Agents; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Therapy, Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Stavudine; Transcription, Genetic; Zalcitabine; Zidovudine | 1992 |
[Treatments of human immunodeficiency virus infection. Current developments].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; HIV; HIV Infections; Humans; Zalcitabine; Zidovudine | 1991 |
New developments in dideoxynucleoside antiretroviral therapy for HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Zalcitabine; Zidovudine | 1991 |
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.
Topics: Animals; Antiviral Agents; Didanosine; DNA Nucleotidyltransferases; DNA Replication; Drug Therapy, Combination; Endopeptidases; HIV Infections; HIV-1; Humans; Integrases; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Resistance; HIV; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Retroviridae; Reverse Transcriptase Inhibitors; T-Lymphocytes, Helper-Inducer; Virus Replication; Zalcitabine; Zidovudine | 1991 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Pregnancy; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1991 |
Treatment of human immunodeficiency virus-infected infants and young children with dideoxynucleosides.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Tolerance; HIV; HIV Infections; Humans; Infant; Zalcitabine; Zidovudine | 1990 |
Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine.
Topics: Clinical Protocols; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Random Allocation; Zalcitabine; Zidovudine | 1990 |
Dideoxycytidine: current clinical experience and future prospects. A summary.
Topics: Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Forecasting; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
88 trial(s) available for zalcitabine and HIV Coinfection
| Article | Year |
|---|---|
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Selection, Genetic; Thymidine; Zalcitabine; Zidovudine | 2003 |
Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Cytidine Triphosphate; Dose-Response Relationship, Drug; Drug Administration Schedule; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Middle Aged; Reverse Transcriptase Inhibitors; Sequence Analysis, RNA; Viral Load; Zalcitabine | 2004 |
Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans.
Topics: Animals; Antiviral Agents; Dogs; Emtricitabine; Female; HIV Infections; Humans; Macaca mulatta; Male; Pregnancy; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Zalcitabine | 2005 |
Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Plasma; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Urine; Zalcitabine | 2005 |
Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Topics: Adult; Anti-HIV Agents; Astragalus propinquus; Carthamus tinctorius; Double-Blind Method; Drug Therapy, Combination; Female; Glycyrrhiza; HIV Infections; Humans; Male; Middle Aged; Phytotherapy; Plant Preparations; Thailand; Treatment Outcome; Zalcitabine; Zidovudine | 2005 |
Meeting notes from the 3rd IAS Conference. New drugs.
Topics: Brazil; CCR5 Receptor Antagonists; Congresses as Topic; Cytidine Triphosphate; Darunavir; HIV Infections; Reverse Transcriptase Inhibitors; Sulfonamides; Zalcitabine | 2005 |
More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175.
Topics: Adult; Anti-Retroviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Receptors, CCR5; Receptors, CXCR4; Zalcitabine; Zidovudine | 2007 |
The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.
Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 2008 |
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Topics: Antiviral Agents; Base Sequence; CD4 Lymphocyte Count; Cell Line; Codon; Drug Resistance, Microbial; Drug Therapy, Combination; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Serial Passage; Zalcitabine; Zidovudine | 1995 |
Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Confidence Intervals; Didanosine; Disease Progression; Drug Monitoring; HIV Infections; Humans; National Institutes of Health (U.S.); Prognosis; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index; United States; Zalcitabine | 1995 |
Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children.
Topics: Adult; Antiviral Agents; Child; Child, Preschool; Female; Half-Life; HIV Infections; Humans; Infant; Male; Zalcitabine | 1995 |
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Biopterins; CD4 Lymphocyte Count; Disease Progression; Dose-Response Relationship, Drug; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Neopterin; Zalcitabine | 1995 |
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; beta 2-Microglobulin; Female; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Time Factors; Zalcitabine | 1995 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1994 |
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Virus Replication; Zalcitabine | 1995 |
Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.
Topics: CD4-Positive T-Lymphocytes; Drug Resistance, Microbial; Drug Therapy, Combination; HeLa Cells; HIV; HIV Infections; Humans; Leukocyte Count; Time Factors; Zalcitabine; Zidovudine | 1994 |
A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-Positive T-Lymphocytes; Didanosine; Female; Follow-Up Studies; HIV Infections; Humans; Leukocyte Count; Male; Risk; Zalcitabine; Zidovudine | 1994 |
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Topics: Adult; Body Weight; CD4-Positive T-Lymphocytes; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocyte Count; Male; Regression Analysis; Severity of Illness Index; Survival Rate; Zalcitabine; Zidovudine | 1993 |
Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; CD4-CD8 Ratio; Cytomegalovirus Retinitis; Drug Therapy, Combination; HIV Infections; Humans; Incidence; Male; Prospective Studies; Zalcitabine; Zidovudine | 1993 |
Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Adult; Antiviral Agents; Biological Availability; Drug Administration Schedule; HIV Infections; Humans; Injections, Intravenous; Male; Middle Aged; Zalcitabine | 1993 |
Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Disease Progression; Follow-Up Studies; HIV Infections; HIV-1; Humans; Regression Analysis; Survival Rate; Treatment Outcome; Zalcitabine | 1996 |
The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Antiviral Agents; Biological Availability; Female; Food; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine | 1995 |
Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Resistance, Microbial; Genotype; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Zidovudine and lamivudine: results of phase III studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Topics: Adult; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Male; Quinolines; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
Topics: Adult; AIDS-Related Complex; Antigen-Antibody Complex; Antiviral Agents; Dose-Response Relationship, Drug; HIV; HIV Core Protein p24; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viremia; Zalcitabine | 1995 |
Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Phenotype; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Lamivudine; Male; Pancreatitis; Risk Factors; RNA, Viral; Treatment Outcome; Zalcitabine | 1996 |
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biopterins; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Neopterin; Polymerase Chain Reaction; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Topics: Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
Topics: Acetamides; Acetophenones; Adult; Antiviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Cross-Over Studies; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Pilot Projects; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Lymphocyte Count; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease.
Topics: Adult; Anti-HIV Agents; British Columbia; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Patient Selection; Practice Patterns, Physicians'; Prospective Studies; Zalcitabine; Zidovudine | 1996 |
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Viral Load; Zalcitabine; Zidovudine | 1996 |
Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cause of Death; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Infant; Male; Neutropenia; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1997 |
Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study.
Topics: Adult; Age Factors; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group.
Topics: Adolescent; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Male; Zalcitabine; Zidovudine | 1997 |
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
Topics: Adult; Anti-HIV Agents; Antigens, Viral; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Homeostasis; Humans; Immunologic Memory; Lymphocyte Activation; Lymphocyte Count; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; T-Lymphocyte Subsets; Tuberculin; Viral Load; Viremia; Zalcitabine; Zidovudine | 1997 |
HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Genes, pol; HIV Infections; HIV-1; Humans; Point Mutation; Prospective Studies; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1997 |
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; Half-Life; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Saquinavir; Zalcitabine; Zidovudine | 1997 |
Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.
Topics: Adult; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; RNA, Viral; Saquinavir; Zalcitabine; Zidovudine | 1997 |
Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Infant; Phenotype; Reverse Transcriptase Inhibitors; Time Factors; Zalcitabine | 1998 |
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Disease Progression; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Multivariate Analysis; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Quality of Life; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; DNA Primers; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Proviruses; Reverse Transcriptase Inhibitors; Viral Load; Zalcitabine; Zidovudine | 1998 |
Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
Topics: Amino Acid Sequence; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Phenotype; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Giant Cells; HIV Infections; HIV-1; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Probability; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Viral Load; Zalcitabine; Zidovudine | 1998 |
A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
[Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus].
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Saquinavir; Zalcitabine; Zidovudine | 1998 |
A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; DNA Mutational Analysis; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Male; Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1999 |
HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Predictive Value of Tests; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Zalcitabine; Zidovudine | 1999 |
Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Quality of Life; Reverse Transcriptase Inhibitors; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine | 1999 |
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Ritonavir; RNA, Viral; Spain; Stavudine; Viremia; Zalcitabine; Zidovudine | 1999 |
Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; HIV Infections; Humans; Quality of Life; Saquinavir; Zalcitabine | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Multivariate Analysis; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation; Phenotype; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Zalcitabine | 2000 |
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; RNA, Viral; Thailand; Zalcitabine; Zidovudine | 2000 |
Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Codon; DNA; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Therapy, Combination; Evaluation Studies as Topic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Nucleosides; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2000 |
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Female; HIV Infections; Humans; Liver; Male; Nucleosides; Prospective Studies; Sex Characteristics; Zalcitabine; Zidovudine | 2000 |
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Motor Skills; Stavudine; Zalcitabine; Zidovudine | 2001 |
FDA Committee recommends clearance for HIVID combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Time Factors; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Final CESARE trial results show continued clinical and survival benefit.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Survival Rate; Zalcitabine; Zidovudine | 1997 |
3TC expanded access program: new requirement for CD4 less than 100.
Topics: CD4 Lymphocyte Count; HIV Infections; Humans; Lamivudine; Zalcitabine | 1995 |
Major study shows AZT monotherapy inferior.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1995 |
Treatment for primary infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Cohort Studies; Controlled Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Placebos; Pyridines; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Abbott laboratories files New Drug Application for ritonavir.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Double-Blind Method; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1996 |
Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
CPCRA 007: preliminary results of combination antiretroviral study.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1996 |
Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2001 |
MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
Topics: Adult; Anti-HIV Agents; Capsules; Drug Administration Schedule; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Count; Male; Middle Aged; Pilot Projects; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine | 2001 |
Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; International Cooperation; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 2001 |
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Headache; HIV Infections; Humans; Infusions, Intravenous; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine | 1992 |
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
Topics: Adult; CD4-Positive T-Lymphocytes; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Core Protein p24; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Zalcitabine; Zidovudine | 1992 |
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.
Topics: Animals; Antiviral Agents; Didanosine; DNA Nucleotidyltransferases; DNA Replication; Drug Therapy, Combination; Endopeptidases; HIV Infections; HIV-1; Humans; Integrases; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Dideoxycytidine (ddC): a potent antiretroviral agent for human immunodeficiency virus infection. An introduction.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine.
Topics: Clinical Protocols; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Random Allocation; Zalcitabine; Zidovudine | 1990 |
Effects of antiretroviral dideoxynucleosides on polymorphonuclear leukocyte function.
Topics: Cell Survival; Chemotaxis, Leukocyte; Didanosine; HIV Infections; HIV-1; Humans; Neutrophils; Phagocytosis; Superoxides; Zalcitabine; Zidovudine | 1990 |
221 other study(ies) available for zalcitabine and HIV Coinfection
| Article | Year |
|---|---|
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide | 2012 |
A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cell Survival; Didanosine; Female; HIV Infections; Humans; Male; Middle Aged; Receptors, CXCR4; Stavudine; T-Lymphocytes, Regulatory; Viral Load; Zalcitabine; Zidovudine | 2017 |
P2Y
Topics: Animals; Anti-HIV Agents; Ganglia, Spinal; HIV Envelope Protein gp120; HIV Infections; Hyperalgesia; Male; Neuralgia; Neuroglia; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Up-Regulation; Zalcitabine | 2018 |
Gene Transfer of Glutamic Acid Decarboxylase 67 by Herpes Simplex Virus Vectors Suppresses Neuropathic Pain Induced by Human Immunodeficiency Virus gp120 Combined with ddC in Rats.
Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Cyclic AMP Response Element-Binding Protein; Decarboxylation; Disease Models, Animal; gamma-Aminobutyric Acid; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Glutamate Decarboxylase; Glutamic Acid; HIV Envelope Protein gp120; HIV Infections; Humans; Male; Mitochondria; Pain Threshold; Phosphorylation; Rats, Sprague-Dawley; Sciatic Nerve; Sciatica; Simplexvirus; Spinal Cord Dorsal Horn; Superoxides; Time Factors; Zalcitabine | 2015 |
Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain.
Topics: Animals; Denervation; Disease Models, Animal; Ganglia, Spinal; Gene Expression Regulation; HIV Envelope Protein gp120; HIV Infections; Male; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; RNA, Messenger; Sensory Receptor Cells; Spinal Nerves; Transfection; Zalcitabine | 2009 |
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Topics: Anti-HIV Agents; Area Under Curve; Biological Availability; Cohort Studies; Drug Combinations; Half-Life; HIV Infections; HIV-1; Humans; Lopinavir; Models, Statistical; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Zalcitabine | 2009 |
Semiparametric analysis of recurrent events: artificial censoring, truncation, pairwise estimation and inference.
Topics: AIDS-Related Opportunistic Infections; Computer Simulation; Data Interpretation, Statistical; Didanosine; HIV Infections; Humans; Kaplan-Meier Estimate; Models, Statistical; Recurrence; Zalcitabine | 2010 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Role of pyrimidine depletion in the mitochondrial cardiotoxicity of nucleoside analogue reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Cardiomyopathies; Cardiotoxins; Dietary Supplements; DNA Copy Number Variations; DNA, Mitochondrial; Electron Transport Complex IV; Heart; HIV Infections; Mice; Mice, Inbred BALB C; Mitochondria, Heart; Mutation; Nucleosides; Pyrimidines; Reactive Oxygen Species; Reverse Transcriptase Inhibitors; Uridine; Zalcitabine; Zidovudine | 2010 |
Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activities.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Treatment Outcome; Zalcitabine | 2012 |
The correlation between pain-related behaviour and spinal microgliosis in four distinct models of peripheral neuropathy.
Topics: Animals; Anti-HIV Agents; Behavior, Animal; Disease Models, Animal; Flow Cytometry; Gliosis; Herpes Zoster; Herpesvirus 3, Human; HIV Envelope Protein gp120; HIV Infections; Hyperalgesia; Immunohistochemistry; Male; Microglia; Peripheral Nerve Injuries; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Spinal Cord; Spinal Nerves; Zalcitabine | 2012 |
[Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; Depression; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Mononucleosis; Male; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Refusal; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load; Viremia; Zalcitabine; Zidovudine | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
Topics: Analysis of Variance; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Drug Combinations; HIV Infections; Humans; Mitochondrial Diseases; Reverse Transcriptase Inhibitors; Self-Sustained Sequence Replication; Sensitivity and Specificity; Zalcitabine; Zidovudine | 2004 |
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
Topics: Acidosis, Lactic; Adult; Cross-Sectional Studies; Didanosine; DNA, Mitochondrial; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lactic Acid; Liver; Male; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients.
Topics: Anti-HIV Agents; Cytidine Triphosphate; HIV Infections; Humans; Mutation; Viral Load; Zalcitabine | 2005 |
Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Molecular Sequence Data; Mutation; Recombination, Genetic; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Virus Replication; Zalcitabine; Zidovudine | 2005 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; Congresses as Topic; Darunavir; Drugs, Investigational; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Peptide Fragments; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Rilpivirine; Societies, Scientific; Sulfonamides; Tenofovir; Zalcitabine | 2005 |
Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy.
Topics: Anti-HIV Agents; Base Sequence; Blood Platelets; Cell Nucleus; Cells, Cultured; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Feasibility Studies; Fibroblasts; HIV Infections; Humans; Indinavir; Lactic Acid; Lamivudine; Leukocytes, Mononuclear; Nucleic Acid Amplification Techniques; Pyruvic Acid; Stavudine; Zalcitabine | 2006 |
dD4FC development discontinued.
Topics: Cytidine Triphosphate; Drug Industry; HIV Infections; Humans; Hyperlipidemias; Reverse Transcriptase Inhibitors; Zalcitabine | 2006 |
Distal sensory polyneuropathy in HIV-positive patients in the HAART era: an entity underestimated by clinical examination.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Electrophysiology; Female; HIV Infections; Humans; Male; Middle Aged; Polyneuropathies; Prevalence; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zalcitabine | 2006 |
[Central nervous system HIV-associated polyarteritis nodosa: long-term outcome].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Central Nervous System Infections; Female; Follow-Up Studies; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Polyarteritis Nodosa; Stavudine; Time Factors; Treatment Outcome; Virus Replication; Zalcitabine | 2006 |
Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cells, Cultured; Drug Interactions; Drug Synergism; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Zalcitabine | 2007 |
Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1.
Topics: Animals; Anti-HIV Agents; Chimera; Dideoxynucleosides; Disease Models, Animal; DNA, Viral; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Macrophages, Peritoneal; Mice; Polymerase Chain Reaction; Spleen; Viral Load; Zalcitabine | 2007 |
Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.
Topics: Cell Line; Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Lymph Nodes; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Zalcitabine | 2008 |
[Antiretroviral treatment against HIV].
Topics: Antiviral Agents; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
FDA advised to license three anti-HIV agents.
Topics: Adult; Antiviral Agents; Child; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine | 1995 |
A quarter-century of antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Combined drugs may be better than zidovudine alone for immunocompromised adults infected with HIV-1.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunocompromised Host; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
[Anti-HIV-therapy. Monotherapy with drugs delaying the course of the disease has limited effect].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Palliative Care; Zalcitabine; Zidovudine | 1994 |
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
Topics: CD4 Lymphocyte Count; Drug Resistance, Microbial; HIV Core Protein p24; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine | 1995 |
Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Peripheral Nervous System Diseases; Retrospective Studies; Risk Factors; Zalcitabine | 1995 |
Combination superior to zidovudine in Delta trial.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Study shows two drugs are best for HIV infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
More HIV patients may benefit from zalcitabine now.
Topics: Drug Therapy, Combination; HIV Infections; Humans; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction.
Topics: Antiviral Agents; Base Sequence; Didanosine; DNA Primers; DNA, Viral; Efficiency; Evaluation Studies as Topic; Genes, pol; Genotype; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Proviruses; Reproducibility of Results; RNA, Viral; Sensitivity and Specificity; Templates, Genetic; Virion; Zalcitabine; Zidovudine | 1994 |
Antiretroviral therapy in HIV-infected adults. Which regimens are recommended?
Topics: Adult; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1994 |
Lower socioeconomic status and shorter survival following HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; British Columbia; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Health Services; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Income; Male; Pneumonia, Pneumocystis; Regression Analysis; Socioeconomic Factors; Survival Rate; Zalcitabine; Zidovudine | 1994 |
[HIV infection--current possibilities in antiviral therapy].
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Pancreatitis; Zalcitabine; Zidovudine | 1994 |
Approval of drugs for HIV infection.
Topics: HIV Infections; Humans; Stavudine; Zalcitabine | 1994 |
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
Topics: Antiviral Agents; Asparagine; Aspartic Acid; Cell Survival; Cells, Cultured; Didanosine; Drug Synergism; HIV Infections; Humans; Hydroxyurea; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Determination of 2'-deoxy-3'-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching.
Topics: Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Reproducibility of Results; Zalcitabine | 1994 |
What to do when zidovudine fails.
Topics: Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Prophylactic zalcitabine and interferon-alpha for a large-bore needlestick exposure to human immunodeficiency virus.
Topics: Adult; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Needlestick Injuries; Recombinant Proteins; Zalcitabine; Zidovudine | 1994 |
Intermittent therapy.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Pharmacotherapy of HIV. APhA Editorial Board on Pharmaceutical Care for Patients with HIV Infection.
Topics: Adult; CD4 Antigens; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Pharmaceutical Services; Zalcitabine; Zidovudine | 1994 |
Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
Topics: Cell Line; Culture Media; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Microscopy, Electron; Time Factors; Zalcitabine; Zidovudine | 1993 |
[Treatment by antiviral drugs of HIV-infected patients].
Topics: Acyclovir; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Interferon-alpha; Zalcitabine; Zidovudine | 1993 |
[A new preparation in the treatment of AIDS patients in Switzerland].
Topics: DNA, Viral; HIV Infections; Humans; Zalcitabine | 1993 |
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine | 1993 |
Population-based estimates of antiretroviral therapy and anti-Pneumocystis prophylaxis in San Francisco: 1991.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Cohort Studies; Dapsone; Didanosine; Drug Combinations; Follow-Up Studies; HIV Infections; Humans; Male; Pentamidine; Pneumonia, Pneumocystis; San Francisco; Sulfamethizole; Trimethoprim; Zalcitabine; Zidovudine | 1993 |
2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients.
Topics: HIV Infections; Humans; Peripheral Nervous System Diseases; Time Factors; Zalcitabine | 1993 |
Antiretroviral therapy.
Topics: Didanosine; Dideoxynucleosides; HIV Infections; Humans; Zalcitabine; Zidovudine | 1993 |
A banner year for AIDS therapy.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Antitubercular Agents; Atovaquone; HIV Infections; Humans; Itraconazole; Ketoconazole; Naphthoquinones; Rifabutin; Rifamycins; United States; United States Food and Drug Administration; Zalcitabine | 1993 |
In vitro immunotoxicity of +/- 2'-deoxy-3'-thiacytidine, a new anti-HIV agent.
Topics: Antiviral Agents; B-Lymphocytes; CD3 Complex; Cytokines; Female; HIV Infections; HIV-1; Humans; Immunoglobulins; Lamivudine; Lymphocyte Activation; Male; Phytohemagglutinins; T-Lymphocytes; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Child; Child, Preschool; Didanosine; HIV Infections; Humans; Immunoglobulins, Intravenous; Infant; Zalcitabine; Zidovudine | 1993 |
[Combination therapy of HIV].
Topics: Antimetabolites; Antiviral Agents; Denmark; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Zalcitabine | 1996 |
Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Conserved Sequence; Deoxycytidine; Didanosine; DNA Primers; Drug Resistance, Microbial; Epitopes; HIV Infections; HIV Reverse Transcriptase; HIV-1; HLA-A2 Antigen; Humans; Lamivudine; Molecular Sequence Data; Oligopeptides; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; T-Lymphocytes, Cytotoxic; Zalcitabine | 1996 |
A new HIV/AIDS drug.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Zalcitabine; Zidovudine | 1996 |
Managing HIV disease after Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1996 |
New drugs for HIV infection.
Topics: Antiviral Agents; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Zalcitabine | 1996 |
Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis.
Topics: Chemical and Drug Induced Liver Injury; Erythema; Female; HIV Infections; Humans; Middle Aged; Zalcitabine; Zidovudine | 1996 |
Lamivudine as adjunct therapy in HIV.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Viral dynamics in hepatitis B virus infection.
Topics: Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Kinetics; Lamivudine; Models, Biological; Regression Analysis; Reverse Transcriptase Inhibitors; Time Factors; Viremia; Virus Replication; Zalcitabine | 1996 |
Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
Topics: Antiviral Agents; Base Composition; Base Sequence; Deoxyribonucleotides; Drug Resistance, Microbial; HIV Antibodies; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Isoquinolines; Lamivudine; Molecular Sequence Data; Mutation; Neutralization Tests; Quinolines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Saquinavir; Virus Replication; Zalcitabine | 1996 |
Monoblastic leukemia in an HIV-infected patient: absence of viral expression in RNA blasts.
Topics: Adult; Bone Marrow; DNA, Viral; Fatal Outcome; Foot Diseases; Gene Expression; HIV Infections; HIV-1; Humans; Immunophenotyping; Leukemia, Monocytic, Acute; Male; Neoplastic Stem Cells; RNA, Viral; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1996 |
Japan's anti-AIDS drug arsenal slowly expands.
Topics: Antiviral Agents; Drug Approval; Drugs, Investigational; HIV Infections; Humans; Japan; Physicians; Protease Inhibitors; Public Opinion; Ritonavir; Thiazoles; United States; Valine; Zalcitabine | 1996 |
Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Drug Utilization; Follow-Up Studies; Hemoglobins; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Multicenter Studies as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1995 |
New nucleoside analogue, lamivudine, released for HIV therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Adverse events from drug therapy for human immunodeficiency virus disease.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Female; HIV Infections; Humans; Male; Pneumonia, Pneumocystis; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination; Urban Health; Zalcitabine; Zidovudine | 1996 |
New guidelines set for occupational HIV exposure.
Topics: Accidents, Occupational; Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Practice Guidelines as Topic; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral monotherapy with nucleoside analogues].
Topics: Antiviral Agents; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
[Resistance and combined use of anti-HIV drugs].
Topics: Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Mutation; Zalcitabine; Zidovudine | 1995 |
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
Topics: Antiviral Agents; Biopsy; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lymph Nodes; RNA, Viral; Viremia; Zalcitabine; Zidovudine | 1996 |
The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
Topics: Advisory Committees; Anti-Infective Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiality; Conflict of Interest; Didanosine; Drug Evaluation; Federal Government; HIV Infections; Humans; National Institutes of Health (U.S.); Organizational Objectives; Professional Staff Committees; Pyrimethamine; Reverse Transcriptase Inhibitors; Risk Assessment; Toxoplasmosis, Cerebral; Treatment Outcome; United States; Zalcitabine; Zidovudine | 1995 |
Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cell Division; Didanosine; HIV Infections; HL-60 Cells; Humans; Zalcitabine; Zidovudine | 1996 |
Combination drug treatment benefits patients with HIV.
Topics: Antiviral Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Prescription of antiretroviral and prophylactic drugs in HIV diseases: reality of medical practices].
Topics: Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Drug Utilization; France; HIV Infections; Hospital Information Systems; Hospital Records; Humans; Pentamidine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1995 |
Therapy of HIV infections: problems and prospects.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Stavudine; Urban Health; Zalcitabine; Zidovudine | 1996 |
Therapy for human immunodeficiency virus infection -- what have we learned?
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[What should be done after needlestick injuries with possible HIV exposure?].
Topics: Antiviral Agents; Drug Therapy, Combination; First Aid; HIV Infections; Humans; Needlestick Injuries; Risk Factors; Zalcitabine; Zidovudine | 1996 |
[The combination of saquinavir and ddC ensures longer survival].
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Saquinavir; Zalcitabine | 1996 |
Occurrence of lymphomas during ddC or ddC/zidovudine combination therapy in persons infected with HIV type 1.
Topics: Antiviral Agents; HIV Infections; HIV-1; Humans; Lymphoma; Zalcitabine; Zidovudine | 1996 |
The Delta trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1997 |
Renal involvement in the diffuse infiltrative CD8 lymphocytosis syndrome.
Topics: Adult; Anti-HIV Agents; CD8-Positive T-Lymphocytes; HIV Infections; Humans; Kidney Diseases; Lymphocytosis; Male; Prednisone; Zalcitabine; Zidovudine | 1997 |
Treatment of late-state HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Reproducibility of Results; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
Irreversible ototoxicity associated with zalcitabine.
Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Deafness; Drug Therapy, Combination; Female; HIV Infections; Humans; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine | 1997 |
Treatment options for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Drug Approval; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lamivudine; Male; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
[Therapeutic strategies against HIV: status in 1994 and future prospectives].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Forecasting; HIV Infections; Humans; Male; Zalcitabine; Zidovudine | 1994 |
Response of HIV-associated thrombocytopenia to triple agent antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Saquinavir; Thrombocytopenia; Zalcitabine; Zidovudine | 1997 |
Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.
Topics: Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; Drug Therapy, Combination; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Longitudinal Studies; RNA, Viral; Stavudine; Viral Load; Viremia; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lamivudine; Membrane Glycoproteins; Reverse Transcriptase Inhibitors; RNA, Messenger; T-Lymphocytes; Time Factors; Transcription, Genetic; Zalcitabine; Zidovudine | 1997 |
[Zalcitabine].
Topics: Adult; Anti-HIV Agents; Digestive System Diseases; Drug Synergism; HIV; HIV Infections; Humans; Peripheral Nervous System Diseases; Retroviridae; Reverse Transcriptase Inhibitors; Zalcitabine | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
[Initial administration of a protease inhibitor delays the progression of AIDS by half time].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Disease Progression; HIV Infections; HIV Protease Inhibitors; Humans; Time Factors; Zalcitabine; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; HIV Infections; Humans; Research Design; Saquinavir; Survival Analysis; Zalcitabine; Zidovudine | 1997 |
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine | 1998 |
Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients.
Topics: Anti-HIV Agents; Cohort Studies; Cost Savings; Costs and Cost Analysis; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Prospective Studies; Zalcitabine; Zidovudine | 1998 |
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Profound anemia in a newborn infant of a mother receiving antiretroviral therapy.
Topics: Adult; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Leukocyte Count; Male; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zalcitabine; Zidovudine | 1998 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
A mixed model for repeated dilution assays.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Models, Statistical; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reproducibility of Results; Viral Load; Zalcitabine; Zidovudine | 1998 |
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zalcitabine; Zidovudine | 1998 |
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Topics: Anti-HIV Agents; Codon; Didanosine; DNA Probes; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 1998 |
The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Cross-Sectional Studies; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Mutation; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1998 |
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cells, Cultured; Didanosine; Drug Resistance, Multiple; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1998 |
[Value of zalcitabine in antiretroviral protocols].
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Treatment Outcome; Zalcitabine | 1998 |
Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Italy; Occupational Exposure; Registries; Retrospective Studies; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
[Benign symmetrical lipomatosis ("peripheral lipodystrophy") during antiretroviral therapy of HIV infection].
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Hemophilia A; HIV Infections; Humans; Indinavir; Lipomatosis, Multiple Symmetrical; Male; Zalcitabine; Zidovudine | 1998 |
Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Didanosine; Drug Therapy, Combination; Enzyme Induction; HIV Infections; HIV-1; Humans; Lymphoid Tissue; Reverse Transcriptase Inhibitors; Telomerase; Telomere; Up-Regulation; Zalcitabine; Zidovudine | 1999 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
PHS recommends preventive drugs for HIV exposures.
Topics: Antiviral Agents; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Pyridines; United States; United States Public Health Service; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1999 |
Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Psoriasis; Reverse Transcriptase Inhibitors; Viral Load; Zalcitabine; Zidovudine | 1999 |
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hospital Costs; Humans; Nevirapine; RNA-Directed DNA Polymerase; United Kingdom; Zalcitabine; Zidovudine | 1999 |
Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; CD4-CD8 Ratio; Choice Behavior; Cognition; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pilot Projects; Psychiatric Status Rating Scales; Psychomotor Performance; Reaction Time; Statistics, Nonparametric; Zalcitabine; Zidovudine | 1999 |
Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Current laboratory assays and in vitro intracellular Th1 and Th2 cytokine synthesis in monitoring antiretroviral therapy of pediatric HIV infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Cytokines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Saquinavir; Th1 Cells; Th2 Cells; Viral Load; Zalcitabine; Zidovudine | 2000 |
Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Interleukin-2; Kinetics; Lymphoid Tissue; Male; Middle Aged; RNA, Viral; Saquinavir; Viremia; Zalcitabine; Zidovudine | 1998 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cysteine; Drug Combinations; Drug Therapy, Combination; Glycine; Glycyrrhetinic Acid; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication.
Topics: Adult; Aged; Anti-HIV Agents; Autonomic Nervous System Diseases; Brain Diseases; Cardiovascular System; Didanosine; Female; Follow-Up Studies; HIV Infections; Humans; Iris Diseases; Male; Middle Aged; Movement; Prevalence; Sensation; Stavudine; Zalcitabine | 2000 |
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2000 |
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 Interna
Topics: Amino Acid Substitution; Codon; Cohort Studies; Didanosine; Drug Resistance, Microbial; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Phenotype; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zalcitabine | 1999 |
Cutaneous side effects induced by indinavir.
Topics: Adult; Alopecia; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Middle Aged; Pruritus; Pyoderma Gangrenosum; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Scalp Dermatoses; Skin; Stavudine; Zalcitabine; Zidovudine | 2000 |
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nucleic Acid Hybridization; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2000 |
Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2000 |
A bend in the road--implications of ACTG 175 and Delta trials.
Topics: Anti-HIV Agents; Australia; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Europe; HIV Infections; HIV-1; Humans; Survival Analysis; United States; Zalcitabine; Zidovudine | 1996 |
Anti-HIV therapy lowers risk of AIDS, death in patients with intermediate-stage HIV disease.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Survival Rate; Zalcitabine; Zidovudine | 1995 |
Saquinavir combination results released.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Organic Chemicals; Saquinavir; Survival Analysis; Zalcitabine | 1996 |
Crixivan reduces viral load.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
AZT studies reinforce benefits of combination.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Lymphocyte Count; Zalcitabine; Zidovudine | 1995 |
Combination 3TC/AZT therapy shows promise.
Topics: CD4 Lymphocyte Count; Codon; Drug Resistance; Drug Therapy, Combination; Drug Tolerance; HIV Infections; Humans; Lamivudine; Mutation; Zalcitabine; Zidovudine | 1995 |
Clinical progress and transmission perils stressed at second human retroviruses conference.
Topics: Acyclovir; AIDS Vaccines; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Herpesviridae; HIV Infections; Humans; Interleukin-2; Lamivudine; Lymphoma, Non-Hodgkin; Retroviridae; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1995 |
Treatment briefs.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Industry; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Nerve Growth Factors; Nervous System Diseases; Pyridines; Recombinant Proteins; Stavudine; Zalcitabine; Zidovudine | 1995 |
New combo trial/same old style.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Protocols; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
3TC rules change again.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Health Care Rationing; Health Priorities; HIV Infections; Humans; Lamivudine; Pharmaceutical Services; United States; Zalcitabine | 1995 |
3TC: the good news and the bad news.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Europe; HIV Infections; Humans; Lamivudine; United States; Zalcitabine; Zidovudine | 1995 |
What we know about anti-HIV drugs.
Topics: Antiviral Agents; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1995 |
3TC expanded access update.
Topics: Antiviral Agents; HIV Infections; Humans; Lamivudine; Zalcitabine | 1995 |
Lamivudine useful against hepatitis B-HIV co-infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Combination antiretroviral treatment: new views, evolving practices.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cells, Cultured; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Peripheral Nervous System Diseases; Protease Inhibitors; Quinolines; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1995 |
A closer look at 3TC. Interview by Mark Mascolini.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Antiretroviral drug resistance.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Viremia; Zalcitabine; Zidovudine | 1995 |
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Indinavir; Interleukin-2; Lamivudine; Mutation; Pyridines; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Roche submits NDA for Invirase.
Topics: Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Investigational New Drug Application; Isoquinolines; Quinolines; Saquinavir; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1995 |
Update on HIV protease inhibitors.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Design; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Phosphorylation; Pyridines; Quinolines; Ritonavir; Saquinavir; Substrate Specificity; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
3TC and saquinavir: we need them now.
Topics: Antiviral Agents; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Roaches of inner space.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Lamivudine; Mutation; T-Lymphocytes, Cytotoxic; Virulence; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine | 1995 |
Closing the circle on HIV--or not.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Nelfinavir; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
A kinder, gentler ddC... for $7,200 a year.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Zalcitabine | 1995 |
3TC/AZT: just another combination.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
FDA approves 3TC and saquinavir. Food and Drug Administration.
Topics: Antiviral Agents; Drug Approval; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine | 1995 |
Combination therapy increases survival.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Lamivudine (3TC) approved for combination use with AZT.
Topics: Adult; Antiviral Agents; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
3TC approved: now for the tough questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Zalcitabine; Zidovudine | 1995 |
Benefits of combination therapy confirmed.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Treatment Failure; Zalcitabine; Zidovudine | 1995 |
Merck protease inhibitor: more news from Retroviruses Conference.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Potent new AIDS drugs underscore promise of combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Approval; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Clinicians experiment with post-exposure drug pairs.
Topics: Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Needlestick Injuries; Occupational Exposure; Zalcitabine; Zidovudine | 1996 |
A surprisingly potent nucleoside analogue.
Topics: Adult; Antiviral Agents; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
AZT and 3TC.
Topics: CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Saquinavir: combination shows survival benefit; new formulation trial recruiting.
Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Survival Rate; Zalcitabine | 1996 |
Update on other antivirals.
Topics: Adenine; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Stavudine; Zalcitabine; Zidovudine | 1996 |
Ritonavir: first to prolong survival.
Topics: Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Ritonavir; Saquinavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1996 |
CDC takes aggressive stance on postexposure prophylaxis. Centers for Disease Control and Prevention.
Topics: Antiviral Agents; Blood-Borne Pathogens; Centers for Disease Control and Prevention, U.S.; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Exposure; Pyridines; Risk Factors; United States; Zalcitabine; Zidovudine | 1996 |
3TC: Glaxo Wellcome broadens patient assistance.
Topics: Antiviral Agents; Drug Industry; Financing, Organized; HIV Infections; Humans; Lamivudine; Zalcitabine | 1996 |
Saquinavir prolongs survival and slows disease progression.
Topics: CD4 Lymphocyte Count; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Survival Rate; Zalcitabine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Top AIDS researchers' strategy for antiretroviral treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Patient Compliance; Practice Guidelines as Topic; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1996 |
3TC: combination trial stopped early as clinical benefit shown.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine | 1996 |
3TC treatment may slow HIV mutations, development of drug resistance.
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Lamivudine; Mutation; Zalcitabine | 1996 |
Eradication of HIV: the cutting edge of clinical trial design.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Decision Making; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Zalcitabine; Zidovudine | 1996 |
ddI and d4T plus protease inhibitors.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Update on nevirapine: quest for a niche.
Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Nevirapine; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Hydroxyurea, a potential new anti-HIV agent.
Topics: Didanosine; DNA Replication; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Leukocytes, Mononuclear; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Antiretroviral therapy for adults and children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Primary Health Care; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1995 |
Association between zalcitabine therapy for human immunodeficiency virus and granuloma annulare?
Topics: Adult; Female; Granuloma Annulare; HIV Infections; Humans; Pain; Remission, Spontaneous; Zalcitabine; Zidovudine | 2001 |
Theoretical mechanistic basis of the toxic effects and efficacy of dideoxycytidine in HIV:AIDS.
Topics: Anti-HIV Agents; HIV Infections; Humans; Models, Theoretical; Reverse Transcriptase Inhibitors; Zalcitabine | 2001 |
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis; Recombination, Genetic; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2001 |
Zalcitabine (Hivid).
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Zalcitabine | 2000 |
The dangers of inferring treatment effects from observational data: a case study in HIV infection.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Observation; Randomized Controlled Trials as Topic; Selection Bias; Zalcitabine; Zidovudine | 2002 |
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Topics: Animals; Anti-HIV Agents; Cytidine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Macaca mulatta; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2002 |
ViroLogic announces agreement with Achillion.
Topics: Clinical Trials, Phase II as Topic; Cooperative Behavior; Drug Industry; Drug Resistance, Viral; Female; Hepatitis B; HIV Infections; Humans; Zalcitabine | 2002 |
Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Topics: Base Sequence; Codon; Czech Republic; Didanosine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Probe Techniques; Molecular Sequence Data; Mutation; Phylogeny; Prevalence; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 2001 |
Combination therapy for HIV infection: getting closer.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
A system for the high efficiency replication of HIV-1 in neural cells and its application to anti-viral evaluation.
Topics: CD4 Antigens; Cell Fusion; Cells, Cultured; HIV Core Protein p24; HIV Infections; HIV-1; Humans; In Vitro Techniques; Neurons; Recombinant Proteins; RNA, Viral; Transfection; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Trial of three drugs for HIV-infected patients.
Topics: Clinical Trials as Topic; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
Esophageal ulceration related to zalcitabine (ddC).
Topics: Adult; Esophageal Diseases; Esophagoscopy; HIV Infections; Humans; Male; Radiography; Recurrence; Ulcer; Zalcitabine | 1992 |
From the Food and Drug Administration.
Topics: Astemizole; Contraindications; Drug Therapy, Combination; HIV Infections; Humans; Terfenadine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1992 |
Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Benzodiazepines; CD4 Antigens; Cytokines; Didanosine; Doxorubicin; Drug Interactions; HIV; HIV Infections; Humans; Imidazoles; Leukocytes, Mononuclear; Lymphocytes; Macrophages; Monocytes; Organ Specificity; Organophosphonates; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Evaluation; HIV Infections; HIV-1; Humans; Nucleosides; Zalcitabine; Zidovudine | 1992 |
Zalcitabine approved under accelerated drug review policy.
Topics: Drug Therapy, Combination; Drugs, Investigational; HIV Infections; Humans; Time Factors; Zalcitabine; Zidovudine | 1992 |
The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Female; HIV Infections; Humans; Maternal-Fetal Exchange; Osmolar Concentration; Placenta; Pregnancy; Zalcitabine; Zidovudine | 1992 |
An optimal control problem for the administration of a drug by using red blood cells as bioreactors.
Topics: Drug Carriers; Erythrocyte Membrane; HIV Infections; Humans; Mathematics; Models, Biological; Pharmaceutical Preparations; Zalcitabine | 1992 |
Testing an anti-HIV trio.
Topics: Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
In vitro toxicity and metabolism of 2',3'-dideoxycytidine, an inhibitor of human immunodeficiency virus infectivity.
Topics: Adenosine Triphosphate; Antiviral Agents; Cell Division; Cell Survival; Cells, Cultured; Deoxycytosine Nucleotides; HIV Infections; Humans; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Monocytes; NAD; Phosphorylation; Tumor Cells, Cultured; Zalcitabine | 1991 |
Bacterial infections in human immunodeficiency virus type 1-infected children: the impact of central venous catheters and antiretroviral agents.
Topics: Adolescent; Antiviral Agents; Bacterial Infections; Catheterization, Central Venous; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Zalcitabine; Zidovudine | 1991 |
Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection.
Topics: Animals; Bone Marrow; Didanosine; Dideoxyadenosine; Female; HIV Infections; Immune System; Immunoglobulin M; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Zalcitabine; Zidovudine | 1991 |
[Combination therapies with anti-retroviral agents in HIV and AIDS infections].
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Interferons; Zalcitabine; Zidovudine | 1991 |
Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Therapy, Combination; Female; HIV Infections; Mice; Mice, Inbred C57BL; Zalcitabine; Zidovudine | 1991 |
Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine.
Topics: Adult; AIDS-Associated Nephropathy; Antiviral Agents; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Male; Peripheral Nervous System Diseases; Zalcitabine | 1991 |
Drugs for HIV infection.
Topics: Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Dideoxycytidine (ddC): a potent antiretroviral agent for human immunodeficiency virus infection. A symposium. February 3, 1990, San Francisco, California. Proceedings.
Topics: Animals; HIV; HIV Infections; Humans; Zalcitabine | 1990 |
Wider access provided to AIDS drugs with actions against HIV, CMV infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Zalcitabine | 1990 |
Clinical trials of combination therapies for HIV infection. Discussion.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Strategies for the combination therapy of HIV infection.
Topics: Acyclovir; Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Virus Replication; Zalcitabine; Zidovudine | 1990 |
A nonlinear three-compartment model for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.
Topics: Delayed-Action Preparations; Drug Carriers; Erythrocytes; HIV Infections; Humans; Models, Biological; Zalcitabine | 1990 |